MorphoSys (NASDAQ:MOR) Shares Gap Up to $4.72

MorphoSys AG (NASDAQ:MORGet Rating) gapped up prior to trading on Tuesday . The stock had previously closed at $4.72, but opened at $5.09. MorphoSys shares last traded at $5.09, with a volume of 1 shares changing hands.

MOR has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft cut their price objective on shares of MorphoSys from €46.00 ($47.92) to €30.00 ($31.25) and set a “hold” rating on the stock in a research report on Tuesday, March 22nd. JMP Securities reiterated a “buy” rating and issued a $41.00 price objective on shares of MorphoSys in a research report on Friday, March 18th. Berenberg Bank initiated coverage on shares of MorphoSys in a research report on Thursday, March 24th. They issued a “buy” rating on the stock. Morgan Stanley cut their price objective on shares of MorphoSys from €50.00 ($52.08) to €40.00 ($41.67) and set an “equal weight” rating on the stock in a research report on Monday, April 4th. Finally, Zacks Investment Research upgraded shares of MorphoSys from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research report on Wednesday, April 13th. Ten investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.67.

The company’s 50 day moving average is $6.16 and its 200 day moving average is $7.89. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.91 and a current ratio of 3.98.

MorphoSys (NASDAQ:MORGet Rating) last announced its quarterly earnings results on Wednesday, March 16th. The company reported ($3.30) earnings per share (EPS) for the quarter. The business had revenue of $62.59 million during the quarter. MorphoSys had a negative net margin of 341.56% and a negative return on equity of 121.54%. Equities analysts predict that MorphoSys AG will post -2.12 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the business. Quadrant Capital Group LLC grew its holdings in shares of MorphoSys by 79.3% in the 4th quarter. Quadrant Capital Group LLC now owns 4,892 shares of the company’s stock worth $46,000 after purchasing an additional 2,164 shares during the last quarter. US Bancorp DE grew its holdings in shares of MorphoSys by 993.6% in the 3rd quarter. US Bancorp DE now owns 8,038 shares of the company’s stock worth $94,000 after purchasing an additional 7,303 shares during the last quarter. Signaturefd LLC lifted its position in MorphoSys by 118.5% during the 4th quarter. Signaturefd LLC now owns 9,420 shares of the company’s stock valued at $89,000 after purchasing an additional 5,108 shares during the period. Wells Fargo & Company MN lifted its position in MorphoSys by 713.2% during the 2nd quarter. Wells Fargo & Company MN now owns 11,491 shares of the company’s stock valued at $221,000 after purchasing an additional 10,078 shares during the period. Finally, Bank of America Corp DE lifted its position in MorphoSys by 325.4% during the 2nd quarter. Bank of America Corp DE now owns 12,014 shares of the company’s stock valued at $231,000 after purchasing an additional 9,190 shares during the period. 1.81% of the stock is currently owned by hedge funds and other institutional investors.

MorphoSys Company Profile (NASDAQ:MOR)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Featured Stories

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.